EXACT Therapeutics AS: Share capital increase registered

24 Dec 2024 12:52 CET

Reference is made to the stock exchange announcements published on 3 December
2024 by EXACT Therapeutics AS (the "Company") regarding the successful placement
of 31,182,795 new shares, of which 21,558,645 shares would be issued in tranche
2 (the "Tranche 2 Offer Shares") and the stock exchange announcement published
on 17 December 2024 regarding the resolution by the extraordinary general
meeting to issue the Tranche 2 Offer Shares.

The issuance of the Tranche 2 Offer Shares has now been registered with the
Norwegian Register of Business Enterprises (Nw: Foretaksregisteret). Following
registration of the share capital increase, the Company’s share capital is NOK
253,053.388 divided into 63,263,347 shares, each with a par value of NOK 0.004.

This information is subject to the disclosure requirements in section 5-12 of
the Norwegian Securities Trading Act.

For more information, please contact:
Per Walday, CEO
EXACT Therapeutics
Email per.walday@exact-tx.com

About EXACT-Tx:
EXACT-Tx is a clinical-stage precision medicine company utilizing the power of
ultrasound and microbubbles to enable targeted drug delivery in oncology.
Acoustic Cluster Therapy (ACT®) follows a unique approach and may be applied to
a wide range of therapeutic agents across a multitude of indications including
within oncology and brain diseases. www.exact-tx.com

More information:
Access the news on Oslo Bors NewsWeb site